Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 20, 2026, 3:24 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 29 matching trials from the live ClinicalTrials.gov search.
Conditions
Bladder Cancer, Urothelial Carcinoma, Metastatic Urothelial Carcinoma, Renal Pelvis Carcinoma, Ureter Carcinoma, Urinary Bladder Carcinoma, Urethra Carcinoma, Muscle Invasive Bladder Cancer
Interventions
Rucaparib
Drug
Lead sponsor
pharmaand GmbH
Industry
Eligibility
18 Years and older
Enrollment
97 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
41
States / cities
Scottsdale, Arizona • La Jolla, California • Los Angeles, California + 35 more
Conditions
Bladder Cancer
Interventions
Tissue Biopsy, Magnetic Resonance Imaging (MRI)
Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Not listed
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
1
States / cities
Houston, Texas
Conditions
Muscle Invasive Bladder Urothelial Carcinoma
Interventions
Enfortumab vedotin, Pembrolizumab
Drug
Lead sponsor
Matthew Galsky
Other
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
5
States / cities
Duarte, California • Indianapolis, Indiana • New York, New York + 1 more
Conditions
Muscle-Invasive Bladder Carcinoma, Tumor
Interventions
Trimodal therapy (TMT) within 45 days of neoadjuvant chemotherapy (NAC)
Drug
Lead sponsor
Leslie Ballas
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Los Angeles, California
Conditions
Bladder Cancer, Urothelial Carcinoma, Muscle-Invasive Bladder Carcinoma, Muscle-invasive Bladder Urothelial Carcinoma
Interventions
Enfortumab vedotin, Pembrolizumab, Cisplatin, Gemcitabine, Fluorouracil, Mitomycin c, Radical cystectomy, Radiation therapy
Drug · Procedure
Lead sponsor
Fox Chase Cancer Center
Other
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Conditions
Muscle-Invasive Bladder Carcinoma, Bladder Cancer
Interventions
CG0070, Nivolumab
Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
Tampa, Florida
Conditions
Urinary Bladder Neoplasms
Interventions
Cetrelimab, TAR-200, Cisplatin, Gemcitabine, Conventional radiation therapy, Hypo-fractioned radiation therapy
Biological · Drug · Radiation
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
518 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2028
U.S. locations
28
States / cities
Loma Linda, California • Los Angeles, California • Santa Monica, California + 25 more
Conditions
Urinary Bladder Neoplasms
Interventions
Pembrolizumab, Conventional Radiotherapy (Bladder only), Conventional Radiotherapy (Bladder and pelvic nodes), Hypofractionated Radiotherapy (Bladder only), Cisplatin, Fluorouracil (5-FU), Mitomycin C (MMC), Gemcitabine, Placebo to Pembrolizumab
Drug · Radiation
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
520 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2031
U.S. locations
24
States / cities
Washington D.C., District of Columbia • Bay Pines, Florida • Orlando, Florida + 20 more
Conditions
Bladder Cancer, Bladder Tumor, Muscle-Invasive Bladder Cancer
Interventions
Nivolumab, Radical cystectomy (RC), Bempegaldesleukin
Biological · Procedure
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
114 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
15
States / cities
Gilbert, Arizona • Tucson, Arizona • La Jolla, California + 12 more
Conditions
Muscle Invasive Bladder Cancer
Interventions
AZD4547, MEDI4736, Olaparib, AZD1775, Vistusertib, AZD9150, Selumetinib
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
117 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2026
U.S. locations
8
States / cities
Los Angeles, California • New Haven, Connecticut • Fort Myers, Florida + 3 more
Conditions
Muscle Invasive Bladder Cancer
Interventions
Durvalumab, Cisplatin, Gemcitabine
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
1,063 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
18
States / cities
Birmingham, Alabama • Los Angeles, California • Palo Alto, California + 15 more
Conditions
Urinary Bladder Cancer, Muscle-invasive
Interventions
Pembrolizumab, Surgery (radical cystectomy (RC) plus Pelvic Lymph Node Dissection [PLND]), Enfortumab Vedotin
Drug · Procedure
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
595 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
39
States / cities
Mobile, Alabama • Little Rock, Arkansas • Fullerton, California + 31 more
Conditions
Bladder Cancer
Interventions
Pembrolizumab, Enfortumab vedotin (EV), RC + PLND, Gemcitabine, Cisplatin
Biological · Procedure · Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
808 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
22
States / cities
Phoenix, Arizona • Fullerton, California • Los Angeles, California + 19 more
Conditions
Bladder Cancer
Interventions
Pembrolizumab, Entinostat, Procedure/Surgery
Drug · Procedure
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years to 99 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
2
States / cities
Chapel Hill, North Carolina • Philadelphia, Pennsylvania
Conditions
NMIBC, MIBC, Muscle Invasive Bladder Cancer (MIBC), Non Muscle Invasive Bladder Cancer
Interventions
This is a non-interventional, observational, prospective study.
Other
Lead sponsor
Bladder Cancer Advocacy Network
Other
Eligibility
18 Years and older
Enrollment
1,400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2032
U.S. locations
1
States / cities
Dallas, Texas
Conditions
Muscle-invasive Bladder Cancer
Interventions
Atezolizumab, Placebo, Signatera
Drug · Other · Device
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
761 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
3
States / cities
Rockledge, Florida • Cleveland, Ohio • Pittsburgh, Pennsylvania
Conditions
Bladder Cancer
Interventions
Pembrolizumab, Gemcitabine, Cisplatin, Surgery (radical cystectomy (RC) plus Pelvic Lymph Node Dissection [PLND]), Placebo
Drug · Procedure
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
907 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
24
States / cities
La Jolla, California • Santa Monica, California • Washington D.C., District of Columbia + 21 more
Conditions
Muscle Invasive Bladder Cancer (MIBC)
Interventions
ctDNA testing
Diagnostic Test
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2032
U.S. locations
1
States / cities
Cleveland, Ohio
Conditions
Muscle Invasive Bladder Cancer
Interventions
APL-1202 in combination with tislelizumab, Tislelizumab alone
Drug
Lead sponsor
Jiangsu Yahong Meditech Co., Ltd aka Asieris
Industry
Eligibility
18 Years and older
Enrollment
79 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
New York, New York
Active, not recruiting Early Phase 1 Interventional

Bladder Preservation or Cystectomy for MIBC

NCT07821177
Conditions
Muscle-Invasive Bladder Carcinoma, Bladder Cancer, Urothelial Carcinoma
Interventions
Gemzar, Cisplatin, Adrucil, Mitomycin, Radical Cystectomy
Drug · Procedure
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
2
States / cities
Boston, Massachusetts
Conditions
Muscle Invasive Bladder Cancer
Interventions
Nivolumab, Cisplatin, Gemcitabine
Drug
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
18 Years and older
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
3
States / cities
Boston, Massachusetts • Minneapolis, Minnesota • Salt Lake City, Utah
Conditions
Bladder Cancer, Muscle Invasive Bladder Cancer (MIBC), Muscle Invasive Bladder Cancer Urothelial Carcinoma, Cystectomy
Interventions
Intravenous fluids, ERAS
Other
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Baltimore, Maryland
Terminated Phase 2 Interventional Results available

Avelumab and Radiation in Muscle-Invasive Bladder Cancer

NCT03747419
Conditions
Bladder Cancer, Muscle Invasive Bladder Cancer
Interventions
Avelumab, Radiation
Drug · Radiation
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
2
States / cities
Boston, Massachusetts
Conditions
Bladder Cancer, Metastatic Bladder Cancer, Invasive Bladder Cancer
Interventions
Avelumab
Drug
Lead sponsor
Baylor College of Medicine
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
3
States / cities
Houston, Texas